How Much Does It Cost to Reach IND?

How much does it cost to reach IND?

The honest answer: plan on $2M to $6M to take a small molecule from lead selection through a filed IND, spread across 12 to 18 months. For a biologic, published ranges cluster between $4M and $10M over 15 to 24 months. Those figures cover outsourced work only: the GLP tox package, safety pharmacology, genetic toxicology for small molecules, bioanalytical support, CMC manufacturing, and the regulatory writing. Payroll, lab space, and discovery-stage platform work sit on top.

The spread is wide because the drivers are structural, not negotiable at the margin. Species selection matters most: a rat and dog program prices very differently from a rat and non-human primate program. So does route of administration (an inhaled or intrathecal program needs specialized tox capabilities), indication (oncology programs following ICH S9 can run leaner batteries), and how clean your molecule already is. A once-daily oral small molecule with a simple salt form and a clean Ames screen lands near the bottom of the range. An antibody-drug conjugate will not.

Treat every number on this page as a range, because that is what the market produces. These are typical quotes we see referenced across CRO proposals and published industry ranges in 2026, US pricing unless stated. Quotes expire, slot availability moves pricing quarter to quarter, and EU and Asian CROs routinely come in 20 to 40 percent below comparable US bids. Anyone who hands you a single point estimate for a preclinical budget is guessing with confidence.

The sections below break that total into the line items a CRO will actually quote, show what gates what on the timeline, and flag where first programs overrun.

What do IND-enabling studies actually include?

An IND-enabling program is a defined bundle of studies, not an open-ended research phase. FDA wants evidence that your proposed starting dose is reasonably safe in humans, that you can measure the drug in plasma, and that you can manufacture consistent material. Every study in the package serves one of those three questions.

For a small molecule, the standard scope covers six workstreams, itemized below.

Biologics swap several pieces. Genetic toxicology is generally waived under ICH S6(R1). Safety pharmacology endpoints usually fold into the NHP toxicology study rather than running standalone. Bioanalytical shifts from LC-MS/MS to ligand-binding assays plus anti-drug antibody methods. And CMC grows from a supporting line into the dominant cost center, which is why the two modalities get separate columns in the table below.

• Pivotal GLP toxicology: 28-day repeat-dose studies in a rodent and a non-rodent (typically rat and dog), with recovery arms and full histopathology
• Safety pharmacology core battery per ICH S7A: hERG patch clamp, cardiovascular telemetry in the non-rodent, respiratory plethysmography, and a functional observational battery
• Genetic toxicology per ICH S2(R1): bacterial reverse mutation (Ames), an in vitro mammalian cell assay, and an in vivo micronucleus
• Toxicokinetics nested inside the tox studies, supported by validated bioanalytical methods (LC-MS/MS for small molecules)
• CMC: a characterized non-GMP tox batch, a GMP clinical batch, formulation work, and stability initiation
• Regulatory: a pre-IND meeting, then IND authoring and eCTD publishing

What does the line-item IND budget look like by workstream?

The table below is the budget skeleton we would sketch for a founder on a whiteboard. Pivotal GLP toxicology is usually the single largest study line at $1M to $2M. The safety pharmacology core battery adds $270K to $530K for a small molecule. The genotox battery is comparatively cheap at $75K to $135K, which surprises people who expect regulatory studies to scale with importance rather than with animal numbers and instrument time.

Bioanalytical work runs $150K to $350K at the program level across method development, validation, and sample analysis. It is quoted per matrix and per species, so a rat, dog, and human-plasma method stack adds up faster than founders expect. IND authoring and publishing runs $75K to $200K depending on how much of Module 3 your CMC vendors draft for you, and pre-IND meeting preparation adds $30K to $80K.

If you want these ranges turned into numbers for your specific program, the free IND Budget Calculator builds a line-item budget from your modality, species, and CMC assumptions instead of making you extrapolate from someone else's averages.

Why does CMC decide whether you run a $3M or an $8M program?

For a small molecule, CMC through IND typically runs $300K to $1M: a non-GMP campaign of tox API, a GMP clinical batch, and the analytical work around both. Formulation development adds $75K to $250K, less if a powder-in-bottle or simple solution presentation is defensible for Phase 1. It is a meaningful line, but it is not the program.

For a biologic, CMC is the program. Cell line development alone runs $300K to $500K and sits at the front of the critical path. Process development follows, then a GMP drug substance campaign, and the chain totals $2M to $5M before you have vialed clinical material. Fill-finish slots book out months in advance, so drug product scheduling deserves attention long before the drug substance batch exists.

This is the structural reason a biologic IND costs roughly double a small molecule IND. The tox packages are not wildly different in price. The manufacturing is. When a biologic founder asks where to focus negotiation effort, the answer is almost always the CMC scope: batch size, number of engineering runs, what analytical development is included, and who owns the cell line and process know-how at the end.

How long do IND-enabling studies take, and what gates what?

Twelve to 18 months for a small molecule, 15 to 24 for a biologic, measured from lead selection to a filed IND. The IND timeline is set less by any single study than by the dependency chain, because the expensive studies cannot start until cheaper, slower things finish.

One practitioner shortcut worth knowing: FDA accepts unaudited draft toxicology reports in the initial IND if you commit to submitting the audited finals within 120 days. Used well, that pulls the submission forward by a quarter. Used badly, with a draft whose conclusions later change, it buys a much worse conversation with the agency.

The gating chain, start to finish:

• Tox material gates everything: the pivotal GLP studies cannot dose until a characterized tox batch exists. For a biologic, that means cell line and process work has already consumed a year or more
• Bioanalytical methods gate data: plasma samples from the tox studies are worthless until a validated method exists to analyze them. Method development started late is the most common self-inflicted delay
• Dose range-finding gates the pivotal studies: short non-GLP DRF studies set the doses for the 28-day GLP studies
• Reports gate the filing: in-life is only about a month, but histopathology, TK analysis, and audited reporting commonly add 3 to 4 months after last dose
• FDA gates first dose: the IND goes into effect 30 days after receipt unless the agency issues a clinical hold

Where do first-time founders blow the IND budget?

The overruns are predictable, and almost none of them come from CROs padding quotes. Most budget blowups trace back to something ordered too late rather than something bought too expensively. Sequencing, not pricing.

The recurring ones:

• Underestimating CMC. Tox batches fail characterization, engineering runs get repeated, and a biologic process that looked fine at bench scale behaves differently in the GMP suite. Founders who budget the bottom of the CMC range with no contingency are the ones who go back to investors early
• Starting bioanalytical method work late. If the method is not validated when the GLP study samples arrive, you pay rush fees, or worse, the study waits. Method development belongs at the front of the program, in parallel with dose range-finding
• Change orders. Every amended protocol, added dose group, extra TK timepoint, and extended recovery arm arrives as a change order priced after competitive pressure is gone. It is common for change orders to add a meaningful percentage on top of the signed bid
• Treating IND authoring as an afterthought. Medical writers booked three months out, Module 3 sections waiting on manufacturing vendors, and publishing teams finding gaps in the final week

What can you defer past IND?

ICH M3(R2) is deliberately staged. You do not need every toxicology study before first-in-human dosing, and deferring the right ones is free money for a seed-stage company. What you need at IND supports your Phase 1 dosing duration and population, nothing more.

Deferral is a cash-flow decision, not a scientific shortcut. Everything deferred still gets done. A pre-IND meeting ($30K to $80K well spent) is the right place to confirm FDA agrees with your staging before you commit the budget.

Commonly deferred:

• Chronic toxicology: 3-month and 6- to 9-month repeat-dose studies support longer clinical dosing and can follow the IND, timed to Phase 2 needs
• Definitive DART studies: timing keys to your strategy for enrolling women of childbearing potential under ICH M3(R2). With contraception and pregnancy-testing requirements in the protocol, embryo-fetal development studies can often wait, though EU and Japanese regulators historically want them earlier than FDA
• Carcinogenicity: not needed until the marketing application for most programs
• Long-term stability: you file with the stability data you have and update the IND as ICH Q1A timepoints read out
• Commercial-scale process development: Phase 1 needs a representative, well-characterized process, not your commercial one

How much should you raise to reach IND?

Work backward from the program cost, then add what founders always forget. The outsourced program is $2M to $6M for a small molecule and $4M to $10M for a biologic. Add team, consultants, insurance, and legal. Then add contingency: we suggest sizing 25 to 40 percent above your midpoint estimate, because the failure modes in the previous section are common enough to plan for rather than hope against.

In practice that maps to round sizes. A lean oral small molecule at the low end of the range is feasible on a seed budget if the CMC is simple and the team stays small. Most biologic programs are series A math, or a seed sized well above the median, because the CMC spend arrives early and cannot be staged much. Raising to the midpoint of the range with no buffer is the most common structural mistake in a biotech seed budget built around an IND.

Geography is the other big dial. EU and Asian CROs typically price 20 to 40 percent below US equivalents for GLP tox and CMC work of comparable quality, and OECD GLP studies performed abroad are routinely accepted in US INDs. The tradeoffs are real (time zones, audit travel, slot lead times), but for a capital-constrained company the savings often fund an entire extra workstream.

How do you keep quotes honest without cutting corners?

Get three bids per workstream and normalize them onto one grid before comparing. CRO proposals differ in what they include: one GLP tox quote bundles TK analysis and bioanalytical method transfer, the next quotes them separately, and the headline numbers are meaningless until you line up scope. The same applies to an IND-enabling package price from a single full-service CRO versus a best-of-breed mix: bundling buys convenience and one project manager, at the cost of the pricing tension that comes from suppliers competing line by line.

Read the change-order terms before you sign, because that is where the margin lives. Ask what a protocol amendment costs, what happens to your slot if the tox batch is late, and whether unused animals are credited. Fixed-price bids beat time-and-materials for defined studies; time-and-materials is defensible for method development, where scope is genuinely uncertain.

This is the problem BioBridgeX exists to fix. It is a neutral marketplace: free for buyers, you contract with and pay your suppliers directly, and suppliers pay a 2 percent success fee only when they are awarded the work and paid. Post your program scope once and compare quotes from vetted GLP tox, bioanalytical, and CMC suppliers side by side, instead of chasing proposals one business-development call at a time.